BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA) has announced a final progress update on the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection, Genta’s lead oncology product, in patients with advanced melanoma. The trial recently completed accrual, and final data on progression-free survival (PFS) – a co-primary endpoint in this trial -- are anticipated in the Fall of 2009.
